Amarillo Biosciences (OTCMKTS:AMAR) versus Synaptogenix (NASDAQ:TAOX) Head-To-Head Review

Amarillo Biosciences (OTCMKTS:AMAR) and Synaptogenix (NASDAQ:TAOX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Amarillo Biosciences and Synaptogenix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarillo Biosciences	0	0	0	0	0.00
Synaptogenix	1	0	0	0	1.00

Given Amarillo Biosciences’ higher probable upside, equities analysts clearly believe Amarillo Biosciences is more favorable than Synaptogenix.

Earnings & Valuation

This table compares Amarillo Biosciences and Synaptogenix”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A
Synaptogenix	$300,000.00	111.30	-$28.74 million	($13.28)	-0.34

Amarillo Biosciences has higher earnings, but lower revenue than Synaptogenix.

Profitability

This table compares Amarillo Biosciences and Synaptogenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarillo Biosciences	-41,453.98%	N/A	-574.29%
Synaptogenix	N/A	-163.40%	-133.47%

Risk and Volatility

Amarillo Biosciences has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

Insider & Institutional Ownership

10.3% of Synaptogenix shares are held by institutional investors. 34.4% of Amarillo Biosciences shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Synaptogenix beats Amarillo Biosciences on 6 of the 10 factors compared between the two stocks.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.